National Cancer Institute, Naples: all 113 studies

Page 1 of 2. Open to participants first (39), then studies with results posted, then the rest; newest registration first within each.

• Single Microdose Trial- CXCR4 PET Tracer - Pharmacokinetics and Pharmacodynamics of [68Ga]Ga-R54, a Radiopharmaceutical Directed Toward CXCR4 in Patients With Advanced Solid Neoplasia.RecruitingNCT07577206Early Phase 1
• Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4Not yet recruitingNCT07522697Phase 2
• Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom BurdenNot yet recruitingNCT07459920Phase 2
• Financial Toxicity in Patients With Early-stage Breast CancerRecruitingNCT07354165
• Using Artificial Intelligence to Guide Fluid Therapy During Major Cancer Surgery: A Randomized Controlled TrialNot yet recruitingNCT07314853Not applicable
• REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)RecruitingNCT07302451Phase 2
• Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01RecruitingNCT07290894Phase 2
• Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal CancerRecruitingNCT07269249
• Contribution of Oncovascular Surgery in the Treatment of Gynecological Advanced Malignant Diseases.Not yet recruitingNCT07267780
• STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal CancerRecruitingNCT07213570Phase 2
• Simvastatin Efficacy in ARID1A Mutated Advanced gastroESophageal Carcinoma Treated With ImmunotherapyRecruitingNCT07213557Phase 2
• Application of da Vinci SP for Endometrial Cancer Surgical StagingRecruitingNCT07027046
• Tumor Antigen Discovery for Innovative Cancer Immunotherapies in HCC: from Benchside to Bedside (HepAnt)RecruitingNCT06905262
• Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker AnalysisRecruitingNCT06905145
• Development of a Platform for the Clinical Implementation of Precision Oncology in the Central-Southern Regions of Italy (COESIT)RecruitingNCT06894823
• Assessment of the Effectiveness of the Metabolomic Approach in Screening for Endometrial CancerRecruitingNCT06893861
• Effectiveness of Nurse Tele-consultation on the Quality of Elective Colonoscopy, Procedure-related Anxiety, and Financial ToxicityRecruitingNCT06887244Not applicable
• Spatial RadiomIcs and TRanscriptomics to the DIscovery of the Cross-link Between Colon Cancer and ChrOnic Kidney DiseaseRecruitingNCT06886282
• Multi-omic Approach to Cancer Diagnosis: the Italian Network of Excellence for Advanced Diagnosis (INNOVA)RecruitingNCT06884878
• ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal CancerRecruitingNCT06714357Phase 2
• Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal CancerRecruitingNCT06509126Phase 3
• Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNomaRecruitingNCT06341764Phase 2
• The ONCOCAMP StudyRecruitingNCT06270602
• Identification of the Pathogenetic Mechanisms Underlying Squamous Cell CarcinomasRecruitingNCT06236464
• PRO for Fighting FT in Ovarian CancerRecruitingNCT06032975
• Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma PatientsRecruitingNCT05821556Phase 2
• Selenoproteins as Prognostic Markers and Therapeutic Targets in Breast Cancer.RecruitingNCT05817227
• Prediction of True Oligo-metastatic Disease.RecruitingNCT05806151
• Study on Gynecological Rare CancersRecruitingNCT05733806
• Molecular Data and Their Correlations With Clinical Outcomes in Gynecological Cancer Patients.RecruitingNCT05733793
• MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.RecruitingNCT05255471Phase 3
• MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal CancerRecruitingNCT05233982Phase 2
• A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)RecruitingNCT04893785Phase 2
• PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients with LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells)RecruitingNCT04854213Not applicable
• Pain ASsessment in CAncer Patients by Machine LEarning (PASCALE)RecruitingNCT04726228
• Endometrial Cancer Conservative Treatment (E.C.Co). A Multicentre ArchiveRecruitingNCT04290299
• Active Surveillance Versus Surgery in Thyroid Papillary MicrocarcinomaRecruitingNCT04129281Not applicable
• Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer PatientsRecruitingNCT03874026Phase 2
• Multicenter Cohort Prospective Study on Multidisciplinary Treatment of Rectal CancerRecruitingNCT01651026
• Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal CancerCompletedNCT01718873Phase 3Results posted
• Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal CancerCompletedNCT01481545Phase 2Results posted
• Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant MelanomaCompletedNCT01359956Phase 3Results posted
• The Study is Observational and Retrospective: Lifestyle, BMI and Activity Physical.Active, not recruitingNCT06866093
• A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)Active, not recruitingNCT06218511Phase 1
• "Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.Active, not recruitingNCT05818865Not applicable
• Multidisciplinary Integrated Platform for a Technological Innvovative Approach to OncotherapiesCompletedNCT05818020
• Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)Active, not recruitingNCT04893356
• MAnagement of METastatic Disease in Campania (MAMETIC)CompletedNCT04595032
• Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal CancerCompletedNCT04425239Phase 2
• Validation of the Italian Version of the PRO-CTCAEStatus unknownNCT04416672
• Aflibercept or Bevacizumab as Second-line Treatment of RAS Mutated Metastatic Colorectal CancerStatus unknownNCT04397601
• Tocilizumab in COVID-19 Pneumonia (TOCIVID-19)Status unknownNCT04317092Phase 2
• Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal CancerStatus unknownNCT04310176Phase 2
• Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.Status unknownNCT04139772Phase 3
• Octreotide LAR in the Induction of Immunologic Response in NENs PatientsCompletedNCT04129255Phase 2
• Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity StudyCompletedNCT04123925Phase 2
• Temozolomide for Second-Line Treatment of Neuroendocrine CarcinomasCompletedNCT04122911Phase 2
• Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational StudyStatus unknownNCT04091204Phase 2
• A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)Status unknownNCT03975114Phase 2
• Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve EfficacyCompletedNCT03891485
• Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial CancerStatus unknownNCT03503786Phase 2
• Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity in ItalyStatus unknownNCT03473379
• Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube CancerStatus unknownNCT03410784Phase 2
• REINFORCEMENT ANASTOMOSIS WITH Modified Cyanacrylate IN Patients Undergoing to Oncologic Colorectal Surgery With Colorectal AnastomosisStatus unknownNCT03380858
• IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma PatientsCompletedNCT03203005Phase 1/2
• Diet, Exercise and Vitamin D in Breast Cancer RecurrenceStatus unknownNCT02786875Phase 3
• Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung CancerStatus unknownNCT02633189Phase 3
• Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and NeckStatus unknownNCT02624128Phase 2
• Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal CancerStatus unknownNCT02619435Phase 2
• PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical TreatmentStatus unknownNCT02618850Not applicable
• Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian CancerStatus unknownNCT02408536
• A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical ProceduresStatus unknownNCT02364791Phase 2
• Observational Study of Incidence of Breakthrough Cancer Pain and How it is TreatedStatus unknownNCT02069067
• PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First ChemotherapyStatus unknownNCT02035683Not applicable
• Preoperative Valproic Acid and Radiation Therapy for Rectal CancerStatus unknownNCT01898104Phase 1/2
• Bevacizumab Beyond Progression in Platinum Sensitive Ovarian CancerStatus unknownNCT01802749Phase 3
• A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal CancerStatus unknownNCT01801904Phase 2
• Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine TumorsTerminatedNCT01755182Phase 3
• Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With BevacizumabStatus unknownNCT01706120Phase 4
• MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung CancerStatus unknownNCT01656551Phase 3
• Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-RasStatus unknownNCT01651013
• Comparison of Bowel Cleansing Regimens Prior to ColonoscopyStatus unknownNCT01649674Phase 4
• Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian CancerCompletedNCT01644825Phase 2
• Second Look Laparoscopy in Colorectal CancerStatus unknownNCT01628211Phase 2
• Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in ChildrenStatus unknownNCT01593488Phase 2
• MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung CancerStatus unknownNCT01405586Phase 3
• Sorafenib in First-line Treatment of Advanced B Child Hepatocellular CarcinomaTerminatedNCT01405573Phase 3
• Predictive Factors of Clinical, Laboratory and Imaging Findings Routinely Used in Diagnosing Thyroid CancerCompletedNCT01074684
• Pathway to Diagnosis of Ovarian CancerStatus unknownNCT01061619
• ELBA: Exemestane and Lapatinib in Advanced Breast CancerWithdrawnNCT01005641Phase 2
• Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical CancerStatus unknownNCT00997009Phase 2
• Safety and Activity Study of Intrathecally Administered Ziconotide for Neuropathic Pain in Patients With CancerStatus unknownNCT00996983Phase 2
• Study Comparing Weekly Versus Every 3 Week Chemotherapy in Patients With Ovarian CancerStatus unknownNCT00660842Phase 3
• Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free IntervalStatus unknownNCT00657878Phase 3
• BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast CancerCompletedNCT00540800Phase 3
• CAPPA-2: Cisplatin Added to Gemcitabine in Poor Performance Advanced NSCLC PatientsTerminatedNCT00526643Phase 3
• STAD-1 Small Cell Lung Cancer Toxicity Adjusted Dosing StudyStatus unknownNCT00526396Phase 3
• CETRA: Neoadjuvant Caelyx and Trastuzumab in Her-2 Positive Breast CancerWithdrawnNCT00434031Phase 2
• VinCaT: Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast CancerStatus unknownNCT00431704Phase 2
• ZANTE: Zometa and Taxotere in Hormone Refractory Prostate CancerCompletedNCT00415779Phase 1

← National Cancer Institute, Naples overview and focus areas